Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.

Détails

ID Serval
serval:BIB_76A8B8796443
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
Périodique
Clinical Cancer Research
Auteur(s)
Ayyoub M., Zippelius A., Pittet M.J., Rimoldi D., Valmori D., Cerottini J.C., Romero P., Lejeune F., Liénard D., Speiser D.E.
ISSN
1078-0432
Statut éditorial
Publié
Date de publication
2003
Peer-reviewed
Oui
Volume
9
Numéro
2
Pages
669-677
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
PURPOSE: As compared with natural tumor peptide sequences, carefully selected analog peptides may be more immunogenic and thus better suited for vaccination. However, T cells in vivo activated by such altered analog peptides may not necessarily be tumor specific because sequence and structure of peptide analogs differ from corresponding natural peptides. EXPERIMENTAL DESIGN: Three melanoma patients were immunized with a Melan-A peptide analog that binds more strongly to HLA-A*0201 and is more immunogenic than the natural sequence. This peptide was injected together with a saponin-based adjuvant, followed by surgical removal of lymph node(s) draining the site of vaccination. RESULTS: Ex vivo analysis of vaccine site draining lymph nodes revealed antigen-specific CD8+ T cells, which had differentiated to memory cells. In vitro, these cells showed accelerated proliferation upon peptide stimulation. Nearly all (16 of 17) of Melan-A-specific CD8+ T-cell clones generated from these lymph nodes efficiently killed melanoma cells. CONCLUSIONS: Patient immunization with the analog peptide leads to in vivo activation of T cells that were specific for the natural tumor antigen, demonstrating the usefulness of the analog peptide for melanoma immunotherapy.
Mots-clé
Amino Acid Sequence, Antigens, Neoplasm, CD8-Positive T-Lymphocytes, Cancer Vaccines, Flow Cytometry, Lymph Nodes, Lymphocyte Activation, Melanoma, Neoplasm Proteins, Peptide Fragments, T-Lymphocytes, T-Lymphocytes, Cytotoxic
Pubmed
Web of science
Création de la notice
28/01/2008 12:14
Dernière modification de la notice
20/08/2019 15:33
Données d'usage